: Pharmacokinetics of Enoxaparin After Coronary Artery Bypass Graft Surgery
Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
To evaluate the pharmacokinetics of thromboprophylactic doses of LMWH enoxaparin in
postoperative CABG patients, drug is administered either as a continuous intravenous infusion
(CIV) or subcutaneous bolus (SCB) once per 72h. Plasma anti-Xa values are measured 12-14
times during study period and concentration maximums calculated to enable comparison of
anti-Xa values between administration routes.